A fast increasing number of inflammatory and auto-immune diseases are being associated with aberrant activation of MIF. These diseases tend to also depend on NLRP3 inflammasome activation.

The initial clinical focus of Apaxen is on pulmonary inflammatory diseases that have a strong fibrotic or tissue remodelling component, such as Chronic Asthma, COPD and IPF. In addition patients with steroid resistant Neutrophilic Asthma could benefit from the steroid efficacy enhancing effects of our MIF inhibitors

Results from these initial indications pave the way to many other indications and patient subsets.